Withdrawal of NINDS Participation in PAR-09-251, "Optimization of Small Molecule Probes for the Nervous System (R21)"

Notice Number: NOT-NS-12-002

Release Date: December 21, 2011

PAR-09-251; PAR-12-060

National Institute of Neurological Disorders and Stroke (NINDS)

This Notice informs potential applicants that the National Institute of Neurological Disorders and Stroke (NINDS) will no longer accept applications under PAR-09-251, "Optimization of Small Molecule Probes for the Nervous System (R21)," beginning with the February 16, 2012 receipt date. Researchers seeking support for chemical optimization of small molecules probes for preclinical, in vivo proof-of-concept experiments for the purposes of drug discovery should consider PAR-12-060, "Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes (R01)."

The following Institutes will continue to participate in PAR-09-251:

National Institute on Drug Abuse (NIDA)
National Institute on Aging (NIA)
National Institute of Mental Health (NIMH)
National Eye Institute (NEI)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

All other aspects of PAR-09-251 will remain unchanged.

Please direct all inquiries to:

Rebecca Farkas, PhD
Office of Translational Research
National Institute of Neurological Disorders and Stroke
6001 Executive Boulevard
Neuroscience Center/Room 2109
Bethesda, MD 20892
Telephone: (301) 496-1779
Fax: 301-402-1501
Email: [email protected]